Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor.

Ge L, Zhang JG, Samathanam CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Nguyen TV, Alipanah R, Pham JT, Sanchez R, Wepsic HT, Morgan TR, Jadus MR.

Cell Immunol. 2009;259(2):117-27. doi: 10.1016/j.cellimm.2009.06.008. Epub 2009 Jun 23.

PMID:
19615673
2.

Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies.

Douglass TG, Driggers L, Zhang JG, Hoa N, Delgado C, Williams CC, Dan Q, Sanchez R, Jeffes EW, Wepsic HT, Myers MP, Koths K, Jadus MR.

Int Immunopharmacol. 2008 Oct;8(10):1354-76. doi: 10.1016/j.intimp.2008.04.016. Epub 2008 Jun 2. Review.

PMID:
18687298
3.

Human allogeneic and murine xenogeneic dendritic cells are cytotoxic to human tumor cells via two distinct pathways.

Schiltz PM, Lee GJ, Zhang JG, Hoa N, Wepsic HT, Dillman RO, Jadus MR.

Cancer Biother Radiopharm. 2007 Oct;22(5):672-83.

PMID:
17979570
4.

Generation of human innate immune responses towards membrane macrophage colony stimulating factor (mM-CSF) expressing U251 glioma cells within immunodeficient (NIH-nu/beige/xid) mice.

Delgado C, Hoa N, Callahan LL, Schiltz PM, Jahroudi RA, Zhang JG, Wepsic HT, Jadus MR.

Cytokine. 2007 Jun;38(3):165-76. Epub 2007 Aug 6.

PMID:
17689258
5.

Human monocytes kill M-CSF-expressing glioma cells by BK channel activation.

Hoa NT, Zhang JG, Delgado CL, Myers MP, Callahan LL, Vandeusen G, Schiltz PM, Wepsic HT, Jadus MR.

Lab Invest. 2007 Feb;87(2):115-29.

6.

Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.

Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575. doi: 10.1158/1078-0432.CCR-06-1576.

7.

Macrophage colony-stimulating factor expression in retrovirally transduced cells is dependent upon both the adherence status of the target cells and its 5' flanking untranslated region.

Zhang JG, Dan Q, Fong TC, Williams CC, Avina MD, Tarbiyat-Boldaji M, Khalaghizadeh S, Irwin M, Nguyen A, Zhuang JL, Hoa N, Wepsic HT, Jadus MR.

Biochem Biophys Res Commun. 2005 May 20;330(4):1275-84.

PMID:
15823581
8.

Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma.

Jeffes EW, Zhang JG, Hoa N, Petkar A, Delgado C, Chong S, Obenaus A, Sanchez R, Khalaghizadeh S, Khomenko T, Knight BA, Alipanah R, Nguyen TV, Shah C, Vohra S, Zhuang JL, Liu J, Wepsic HT, Jadus MR.

J Immunol. 2005 Mar 1;174(5):2533-43.

10.
11.
12.
13.

Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer.

Williams CC, Trinh H, Tran TV, Dan Q, Sanchez R, Delgado C, Chen Y, Sippel B, Jeffes EW, Wepsic HT, Jadus MR.

Mol Ther. 2001 Feb;3(2):216-24.

14.
16.

Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating factor through a phagocytosis-dependent pathway.

Jadus MR, Williams CC, Avina MD, Ly M, Kim S, Liu Y, Narasaki R, Lowell CA, Wepsic HT.

J Immunol. 1998 Jan 1;160(1):361-8.

17.

Detection of a membrane-associated cytokine (macrophage colony stimulating factor) using a modified commercially available ELISA.

Ly M, Irwin MC, Irwin MR, Wepsic HT, Jadus MR.

Biotechniques. 1996 Dec;21(6):980-2. No abstract available.

18.

Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor.

Jadus MR, Irwin MC, Irwin MR, Horansky RD, Sekhon S, Pepper KA, Kohn DB, Wepsic HT.

Blood. 1996 Jun 15;87(12):5232-41.

PMID:
8652838
20.

The identification of the neonatal NBXFO hybridoma cell and its mediator.

Jadus MR, Irwin MR, Barton BE, Irwin MC, Wepsic HT.

Dev Comp Immunol. 1995 May-Jun;19(3):261-77.

PMID:
8595824
21.

Prostaglandin E2 induces up-regulation of murine macrophage beta-endorphin receptors.

Gelfand RA, Wepsic HT, Parker LN, Jadus MR.

Immunol Lett. 1995 Feb;45(1-2):143-8.

PMID:
7542625
22.

Hematopoietic colony stimulatory factor formation by murine mesangial cells: gene expression and biological activity.

Jadus MR, Pai R, Horansky E, Wepsic HT, Kirschenbaum MA, Kamanna VS.

Biochim Biophys Acta. 1994 Nov 10;1224(2):181-8.

PMID:
7981231
23.

Detection of interleukin 2 receptors on murine lymphocytes using fluorescent interleukin 2.

Jadus MR, Horansky E, Wepsic HT.

Immunol Lett. 1992 Oct-Nov;34(2):127-33.

PMID:
1487301
24.

The role of cytokines in graft-versus-host reactions and disease.

Jadus MR, Wepsic HT.

Bone Marrow Transplant. 1992 Jul;10(1):1-14. Review. Erratum in: Bone Marrow Transplant 1993 Jan;11(1):89.

PMID:
1515873
25.
26.

The effects of protein kinase inhibitors on lymphocyte blastogenesis and GVHD-induced splenomegaly.

Wepsic HT, Duffie GP, Ellis NK.

Immunopharmacol Immunotoxicol. 1989;11(1):81-99.

PMID:
2760415
28.

The effects of E series prostaglandins on blastogenic responses in vitro and graft vs. host responses in vivo.

Duffie GP, Romanelli RR, Ellis NK, Young MR, Wepsic HT.

Immunopharmacol Immunotoxicol. 1988;10(4):597-615.

PMID:
3246542
29.

Suppressor alveolar macrophages in mice bearing metastatic Lewis lung carcinoma tumors.

Young MR, Endicott RA, Duffie GP, Wepsic HT.

J Leukoc Biol. 1987 Dec;42(6):682-8.

PMID:
3500255
30.

Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.

Nikcevich DA, Duffie GP, Young MR, Ellis NK, Kaufman GE, Wepsic HT.

Cell Immunol. 1987 Oct 15;109(2):349-59.

PMID:
2959374
32.

Stimulation of hematopoiesis and bone marrow suppressor cells by the subcutaneous injection of linoleic acid.

Young MR, Ellis NK, Young ME, Wepsic HT.

Cell Immunol. 1987 Jun;107(1):238-48.

PMID:
2953447
33.
34.

Stimulation of prostaglandin-dependent macrophage suppressor cells by the subcutaneous injection of polyunsaturated fatty acids.

Ellis NK, Young MR, Nikcevich DA, Newby M, Plioplys R, Wepsic HT.

Cell Immunol. 1986 Oct 15;102(2):251-60.

PMID:
2948662
35.

Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis.

Nikcevich DA, Young MR, Ellis NK, Newby M, Wepsic HT.

J Immunopharmacol. 1986;8(3):299-313.

PMID:
3760591
36.

Modification of in vitro and in vivo BCG cell wall-induced immunosuppression by treatment with chemotherapeutic agents or indomethacin.

DeSilva MA, Wepsic HT, Mizushima Y, Nikcevich DA, Larson CH.

J Natl Cancer Inst. 1985 Apr;74(4):917-21.

PMID:
3157819
37.

The inhibition of fatal graft-versus-host disease by immunization of donor or host with bacillus Calmette-Guérin cell walls.

Janss G, Wepsic HT, Mizushima Y, DeSilva MA, Larson CH.

Transplantation. 1984 Oct;38(4):407-11.

PMID:
6238458
38.

Tumour-induced suppressor macrophages in rats: differences in their suppressive effects on the Con A and PHA responses.

Mizushima Y, Wepsic HT, Yamamura Y, Desilva MA.

Clin Exp Immunol. 1984 Aug;57(2):371-9.

39.

Antitumor therapeutic effect of neurotropin on transplanted tumors in rats.

Mizushima Y, Wepsic HT, Kobayashi H.

Oncology. 1984;41(4):289-92.

PMID:
6462606
40.

Negative and positive immunobiological responses in mice pretreated with Bacillus Calmette-Guérin cell wall.

Mizushima Y, Wepsic HT, Yamamura Y, DeSilva MA, Janns G, Larson CH.

Cancer Res. 1984 Jan;44(1):20-4.

41.

Concurrent primary parathyroid hyperplasia and parathyroid carcinoma.

Haghighi P, Astarita RW, Wepsic HT, Wolf PL.

Arch Pathol Lab Med. 1983 Jul;107(7):349-50.

PMID:
6687992
42.

Overview of oncofetal antigens in cancer.

Wepsic HT.

Ann Clin Lab Sci. 1983 Jul-Aug;13(4):261-6.

PMID:
6194734
43.

Inhibition of the graft-versus-host response by BCGcw-induced suppressor cells or prostaglandin E1.

Wren SM, Wepsic HT, Larson CH, De Silva MA, Mizushima Y.

Cell Immunol. 1983 Mar;76(2):361-71.

PMID:
6220811
44.

BCG-induced macrophages as suppressor cells.

Druker BJ, Wepsic HT.

Cancer Invest. 1983;1(2):151-61. Review. No abstract available.

PMID:
6230140
45.

Characterization of serum protein components from Donryu rats which were immune to hepatoma AH-66 tumor cells.

Wepsic HT, Tsukada Y, Kobayashi K, Hara A, Hirai H.

Jpn J Exp Med. 1982 Aug;52(4):163-71.

PMID:
6184506
46.

Identification and characterization of the BCG cell wall-stimulated suppressor cells in inbred rats.

Druker BJ, Wepsic HT, Alaimo JC, Murray W 4th, Vranes AJ.

Oncodev Biol Med. 1982;3(2-3):209-21.

PMID:
6214769
47.

Purification of specific antibody to alpha-foetoprotein and its immunological effect on cancer cells.

Hirai H, Tsukada Y, Hara A, Hibi N, Nishi S, Wepsic HT, Koji T, Ishii N.

J Chromatogr. 1981 Oct 23;215:195-210.

PMID:
6172437
48.

Effect of horse antibody to rat alpha-fetoprotein upon the growth of AH-66 in Donryu rats.

Wepsic HT, Tsukada Y, Takeichi N, Nishi S, Hirai H.

Int J Cancer. 1980 May 15;25(5):655-61.

PMID:
6154665
49.

Alpha-fetoprotein and its relevance to human disease.

Wepsic HT, Kirkpatrick A.

Gastroenterology. 1979 Oct;77(4 Pt 1):787-96. No abstract available.

PMID:
89060
50.

Bacillus Calmette-Guérin cell wall immunotherapy of intramuscular and metastatic Morris rat hepatomas.

Wepsic HT, Tracey RS, Sell S, Harris S, Ribi E, Morris H.

Cancer Res. 1978 May;38(5):1217-22. No abstract available.

Supplemental Content

Loading ...
Support Center